Molecular Partners Ag Stock Performance
| MOLN Stock | USD 4.14 0.19 4.81% |
The company secures a Beta (Market Risk) of 0.19, which conveys not very significant fluctuations relative to the market. As returns on the market increase, Molecular Partners' returns are expected to increase less than the market. However, during the bear market, the loss of holding Molecular Partners is expected to be smaller as well. At this point, Molecular Partners has a negative expected return of -0.22%. Please make sure to verify Molecular Partners' potential upside, as well as the relationship between the rate of daily change and period momentum indicator , to decide if Molecular Partners performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Molecular Partners AG has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of uncertain performance in the last few months, the Stock's essential indicators remain very healthy which may send shares a bit higher in June 2025. The recent disarray may also be a sign of long period up-swing for the firm investors. ...more
Actual Historical Performance (%)
One Day Return (0.25) | Five Day Return 1.29 | Year To Date Return (19.10) | Ten Year Return (79.95) | All Time Return (79.95) |
1 | Molecular Partners Announces Participation at Upcoming Investor Conferences and 2024 Financial Results Conference Call | 02/28/2025 |
2 | Molecular Partners Reports Highlights from Q4 2024 and Key Financials for Full Year 2024 | 03/06/2025 |
3 | Molecular Partners AG Q4 2024 Earnings Call Transcript | 03/10/2025 |
4 | Molecular Partners to hold three poster presentations at AACR 2025 | 03/25/2025 |
5 | Heres Why Molecular Partners AG Sponsored ADR Could be Great Choice for a Bottom Fisher | 04/03/2025 |
6 | Former AbbVie VP Joins Abivax Board as Critical Phase 3 Ulcerative Colitis Data Approaches - Stock Titan | 04/22/2025 |
7 | J.P. Morgan Sticks to Their Buy Rating for Novo Nordisk - The Globe and Mail | 05/13/2025 |
| Begin Period Cash Flow | 67.3 M |
Molecular | Build AI portfolio with Molecular Stock |
Molecular Partners Relative Risk vs. Return Landscape
If you would invest 492.00 in Molecular Partners AG on February 20, 2025 and sell it today you would lose (97.00) from holding Molecular Partners AG or give up 19.72% of portfolio value over 90 days. Molecular Partners AG is currently does not generate positive expected returns and assumes 5.1096% risk (volatility on return distribution) over the 90 days horizon. In different words, 45% of stocks are less volatile than Molecular, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Molecular Partners Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Molecular Partners' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Molecular Partners AG, and traders can use it to determine the average amount a Molecular Partners' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0427
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | MOLN |
Estimated Market Risk
| 5.11 actual daily | 45 55% of assets are more volatile |
Expected Return
| -0.22 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Molecular Partners is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Molecular Partners by adding Molecular Partners to a well-diversified portfolio.
Molecular Partners Fundamentals Growth
Molecular Stock prices reflect investors' perceptions of the future prospects and financial health of Molecular Partners, and Molecular Partners fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Molecular Stock performance.
| Return On Equity | -0.34 | ||||
| Return On Asset | -0.21 | ||||
| Operating Margin | (12.32) % | ||||
| Current Valuation | (10.17 M) | ||||
| Shares Outstanding | 36.87 M | ||||
| Price To Earning | 1.85 X | ||||
| Price To Book | 0.96 X | ||||
| Price To Sales | 29.31 X | ||||
| Revenue | 4.97 M | ||||
| Gross Profit | (42.53 M) | ||||
| EBITDA | (51.65 M) | ||||
| Net Income | (54.04 M) | ||||
| Cash And Equivalents | 267.13 M | ||||
| Cash Per Share | 8.22 X | ||||
| Total Debt | 2.44 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.37 X | ||||
| Book Value Per Share | 3.84 X | ||||
| Cash Flow From Operations | (59.25 M) | ||||
| Earnings Per Share | (2.02) X | ||||
| Market Capitalization | 145.65 M | ||||
| Total Asset | 158.53 M | ||||
| Retained Earnings | (246.29 M) | ||||
| Working Capital | 143.5 M | ||||
About Molecular Partners Performance
By examining Molecular Partners' fundamental ratios, stakeholders can obtain critical insights into Molecular Partners' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Molecular Partners is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.34) | (0.32) | |
| Return On Capital Employed | (0.41) | (0.44) | |
| Return On Assets | (0.34) | (0.32) | |
| Return On Equity | (0.38) | (0.40) |
Things to note about Molecular Partners performance evaluation
Checking the ongoing alerts about Molecular Partners for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Molecular Partners help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Molecular Partners generated a negative expected return over the last 90 days | |
| Molecular Partners has high historical volatility and very poor performance | |
| The company reported the previous year's revenue of 4.97 M. Net Loss for the year was (54.04 M) with loss before overhead, payroll, taxes, and interest of (42.53 M). | |
| Molecular Partners AG currently holds about 267.13 M in cash with (59.25 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.22, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Latest headline from news.google.com: J.P. Morgan Sticks to Their Buy Rating for Novo Nordisk - The Globe and Mail |
- Analyzing Molecular Partners' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Molecular Partners' stock is overvalued or undervalued compared to its peers.
- Examining Molecular Partners' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Molecular Partners' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Molecular Partners' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Molecular Partners' stock. These opinions can provide insight into Molecular Partners' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Molecular Partners AG. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Global Correlations module to find global opportunities by holding instruments from different markets.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Molecular Partners. If investors know Molecular will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Molecular Partners listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.02) | Revenue Per Share | Quarterly Revenue Growth (1.00) | Return On Assets | Return On Equity |
The market value of Molecular Partners is measured differently than its book value, which is the value of Molecular that is recorded on the company's balance sheet. Investors also form their own opinion of Molecular Partners' value that differs from its market value or its book value, called intrinsic value, which is Molecular Partners' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Molecular Partners' market value can be influenced by many factors that don't directly affect Molecular Partners' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Molecular Partners' value and its price as these two are different measures arrived at by different means. Investors typically determine if Molecular Partners is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Molecular Partners' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.